Apr 25, 2020

KAT7 is a therapeutic vulnerability of MLL-rearranged acute myeloid leukemia

BioRxiv : the Preprint Server for Biology
Yan Zi AuK. Yusa

Abstract

Histone lysine acetyltransferases (HATs/KATs) catalyze the transfer of acetyl groups from acetyl-CoA to lysines of core histones, playing a central role in transcriptional regulation, which when dysregulated lead to diseases. Through genome-wide CRISPR-Cas9 screens we recently identified several HATs of the MYST family that show cell-specific essentiality and therefore may represent potential novel therapeutic targets for acute myeloid leukaemia (AML). Here we investigate the essentiality of lysine acetyltransferase KAT7 in AMLs driven by MLL fusions. We find that KAT7 loss leads to a rapid and dramatic global reduction in both H3K14ac and H4K12ac in association with reduced proliferation, increased apoptosis or enhanced differentiation of AML cells driven by MLL-X fusions. We go on to show that KAT7 activity is required for the recruitment of the MLL-fusion associated adaptor proteins such as BRD4 to gene promoters, which are critical for the maintenance of the MLL-AF9 transcriptional programme. Our findings propose that KAT7 is a plausible therapeutic target for this poor prognosis subtype of AML.

  • References
  • Citations

References

  • We're still populating references for this paper, please check back later.
  • References
  • Citations

Citations

  • This paper may not have been cited yet.

Mentioned in this Paper

Fluctuation
DNA Methylation [PE]
Nucleosomes
Regulation of Molecular Function, Epigenetic
Complement System Proteins
Genome
Transcription, Genetic
Neurons
Spatial Distribution
DNA Methylation

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.